Content area

|
|

Immunterapi til patienter med malignt melanom og hjernemetastaser

Forfatter(e)
Line Thing Simonsen*1, Anne Mette Sjørslev Schmidt*1, Trine Heide Øllegaard1, Inge Marie Svane2, Lars Bastholt3, Adam Andrzej Luczak4 & Henrik Schmidt1
1) Kræftafdelingen, Aarhus Universitetshospital 2) Onkologisk Afdeling, Herlev Hospital 3) Onkologisk Afdeling, Odense Universitetshospital 4) Onkologisk Afdeling, Aalborg Universitetshospital

Ugeskr Læger 2019;181:V01190057
Reference: 
Ugeskr Læger 2019;181:V01190057

Line Thing Simonsen*, Anne Mette Sjørslev Schmidt*, Trine Heide Øllegaard, Inge Marie Svane, Lars Bastholt, Adam Andrzej Luczak & Henrik Schmidt:

Immunotherapy for patients with malignant melanoma and brain metastases

Ugeskr Læger 2019;181:V01190057

Melanoma has a high propensity to form brain metastases, and in this review, we discuss the treatment options for brain metastases. These have previously been sparse, but with the introduction of targeted therapy and checkpoint inhibitors, studies including patients with brain metastases have been published. Recent studies investigating combination of either dabrafenib and trametinib or ipilimumab and nivolumab have proved promising. Based on phase II studies, the most effective treatment for patients with asymptomatic brain metastases seems to be ipilimumab and nivolumab. Symptomatic brain metastases are presently being further investigated.

*) Contributed equally to this study.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Christian Søren Christiansen | 19/11
2 kommentarer
af Pål Ledaal | 18/11
3 kommentarer
af Hanne Pedersen | 17/11
1 Kommentar
af Mads Aage Toft Kristensen | 16/11
1 Kommentar
af Ketil Bjerregård | 15/11
1 Kommentar
af Jens Lund Ahrenkiel | 15/11
1 Kommentar
af Nicolaj Markus Stilling | 15/11
2 kommentarer